Another twist in the TIGIT saga
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
ASCO 2023 – Morpheus spurs Roche to take the red pill
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.
